OptiNose

TrialNetworks appoints Jorge G. Guerra advisory board chairman

Monday, January 20, 2014

Jorge G. Guerra, M.D., has joined TrialNetworks as chairman of the advisory board. The TrialNetworks platform, which began as an innovative site engagement and communication portal, has rapidly grown into a comprehensive cloud-based solution for key aspects of a clinical trial from startup through closeout, including feasibility surveys, training, trial conduct efficiency, patient recruitment and retention, site activation and document management.

[Read More]

Avanir, OptiNose in licensing deal

Wednesday, July 3, 2013

Avanir Pharmaceuticals and OptiNose have entered into an exclusive North American license agreement for the development and commercialization of OptiNose’s novel Breath Powered intranasal delivery system containing low-dose sumatriptan powder to treat acute migraine. If approved, this product would be the first dry-powder nasal delivery form of sumatriptan.

[Read More]